Allos' Folotyn extends PFS and defers resistance to other drugs in lymphoma
This article was originally published in Scrip
Executive Summary
A retrospective study of Allos Therapeutics' folate analogue, Folotyn (pralatrexate), suggests that the drug reverses the pattern of progressive resistance usually observed in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The firm plans to use that data as part of its submission to the European regulatory authorities.